AUTO CAR T cell therapy 비교 | 바이오정보모아

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview Toxicology Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 2 AUTO CAR T cell therapy (AUTO CAR T cell therapy) Autolus Limited·Patients Followed for up to 15 Yea… 1 trials

Overview Program	AUTO CAR T cell therapy
Overview Company	Autolus Limited
Overview Modality	CGT
Overview Target	Patients Followed for up to 15 Years Fol
Overview Indication	Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma
Overview Phase	PHASE_2
Overview Status	ACTIVE
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

Toxicology Major finding	thrombocytopenia (OR, 1
Toxicology CRS	Reported

Clinical Safety signal	thrombocytopenia (OR, 1
Clinical Program phase	PHASE_2

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview Toxicology Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 2 AUTO CAR T cell therapy (AUTO CAR T cell therapy) Autolus Limited·Patients Followed for up to 15 Yea… 1 trials

Overview Program	AUTO CAR T cell therapy
Overview Company	Autolus Limited
Overview Modality	CGT
Overview Target	Patients Followed for up to 15 Years Fol
Overview Indication	Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma
Overview Phase	PHASE_2
Overview Status	ACTIVE
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

Toxicology Major finding	thrombocytopenia (OR, 1
Toxicology CRS	Reported

Clinical Safety signal	thrombocytopenia (OR, 1
Clinical Program phase	PHASE_2